CDKN2A and neoplasm: Row-clade b, which lacks either BRAF_MUT or CDKN2a.p14_MUT, is comprised of twelve drugs (681640, NU-7441, BAY_61.3606, AZD-2281, camptothecin, PD-173074, DMOG, methotrexate, IPA-3, ABT-263, gemcitabine and bicalutamide) and consists of a mixture of MUTs with significant differences between sensitive and resistant tumor cells.